Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P370. Short onset of ulcerative colitis predicts the response to cyclosporine (Neoral) as bridge therapy in steroid-refractory ulcerative colitis
Authors:

M. Mastronardi1, P. Giorgio1, 1IRCCS “S. De Belllis”, Gastroenterology and Digestive Endoscopy, Castellana Grotte, Italy

P370

IBD-Control Questionnaire: validation and evaluation in clinical practice

Authors:

I. Ribeiro*1, C. Fernandes2, J. Silva2, A. Ponte2, J. Carvalho2

1Hospital Center of Vila Nova Gaia, Gastroenterology Department, Vila Nova Gaia, Portugal, 2Centro Hospitalar de Gaia/Espinho, Gastroenterology, Gaia, Portugal

P371.

Prospective study of prevalence and incidence of vertebral fractures in long-term anti-TNF alpha maintenance therapy treatment for inflammatory bowel disease

Authors:

B. Maldonado Pérez1, M.Á. Vázquez Gámez2, L. Castro Laria1, M.J. Montoya García2, R. Pérez Cano2, J.M. Herrerías Gutiérrez1, 1Hospital Universitario Virgen Macarena, Gastroenterology, Seville, Spain, 2University of Seville, Medicine Department, Seville, Spain

P371. Short- and long-term efficacy of infliximab in intestinal Behcet's disease refractory to conventional medications indicates a major role for tumour necrosis factor-alpha
Authors:

H. Kinoshita1, R. Kunisaki1, S. Tomohiko1, H. Kimura1, S. Maeda2, 1Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan, 2Yokohama City University, Department of Gastroenterology, Yokohama, Japan

P371. Sonographic lesion index for Crohn's disease assesses small bowel damage after biologic therapy
P371. Vaccination against opportunistic infections in patients with inflammatory bowel disease on immunomodulator therapy
P371

Are biologics a safe option for elderly patients with inflammatory bowel disease?

Authors:

L. Sparks*, S. Mann

Barnet & Chase Farm Hospitals, Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P372.

Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients

Authors:

M. Chaparro1, J. Gordillo2, E. Domènech3, M. Esteve4, M. Barreiro-de Acosta5, A. Villoria6, E. Iglesias-Flores7, P. Huelín8, J. Naves3, O. Benítez4, L. Nieto5, X. Calvet6, V. García-Sánchez7, J. Villagrasa9, A.C. Marín10, M. Ramas1, I. Moreno11, J. Maté1, J.P. Gisbert1, 1Hospital Universitario de La Princesa, IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 4Hospital Universitario Mutua de Terrassa and CIBERehd, Gastroenterology Unit, Terrasa, Spain, 5Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital de la Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 9Hospital Universitario de La Princesa and IP, Preventive Medicine Unit., Madrid, Spain, 10Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario de La Princesa and IP, Fundación de Investigación Biomédica, Madrid, Spain

P372. Predicting long-term response to anti-TNFα in Crohn's disease
P372. Preliminary results from a prospective study on Clostridium difficile prevalence, toxino type and antibiotic sensitivity in inflammatory bowel disease patients
P372. Severe obesity in Crohn's disease patients: prevalence and disease associations
Authors:

B. Ungar1, U. Kopylov2, D. Goitein3, A. Lahat2, E. Bardan2, B. Avidan2, A. Lang2, Y. Maor2, R. Eliakim2, S. Ben-Horin2, 1Sheba Medical Center, Internal Medicine D, Ramat Gan, Israel, 2Sheba Medical Center, Gastroenterology Institute, Ramat Gan, Israel, 3Sheba Medical Center, Surgery C, Ramat Gan, Israel

P372

Efficacy and safety of endoscopic balloon dilatation in the Inflammatory Bowel Disease: Results of the ENEIDA database.

Authors:

X. Andújar Murcia*1, C. Loras1, M. Socarras2, E. Rodriguez3, B. Sicilia4, E. Iglesias5, M.J. Casanova6, Y. Ber7, J. Martínez-González8, I. Rodríguez9, L. Bujanda10, D. Montfort11, X. Calvet12, J. Barrio13, M. Calaf14, J. Guardiola15, Y. Zabana16, F. Fernández-Bañares16, M. Esteve16

1Hospital Universitari Mutua de Terrassa, Endoscopy, Terrassa, Spain, 2Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain, 3Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, 4Complejo Asistencial Universitario de Burgos, Gastroenterology, Burgos, Spain, 5Hospital Universitario Reina Sofia, Gastroenterology, Córdoba, Spain, 6Hospital Universitario de la Princesa, Gastroenterology, Madrid, Spain, 7Hospital Clínico Universitario Lozano-Blesa, Gastroenterology, Zaragoza, Spain, 8Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 9Hospital Galdakao-Usansolo, Gastroenterology, Bilbao, Spain, 10Hospital Universitario Donostia, Gastroenterology, San Sebastian, Spain, 11Hospital Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain, 12Hospital Parc Taulí de Sabadell, Gastroenterology, Sabadell, Spain, 13Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain, 14Hospital Universitari Germans Trías i Pujol, Gastroenterology, Barcelona, Spain, 15Hospital Universitari de Bellvitge, Gastroenterology, Hospitalet del Llobregat, Spain, 16Hospital Universitari Mutua de Terrassa, Gastroenterology, Terrassa, Spain

P373. Faecalibacterium prausnitzii is also reduced in ulcerative colitis
P373.

Profiles of dental caries and periodontal disease in individuals with or without inflammatory bowel disease (IBD)

Authors:

V. Koutsochristou1, A. Tsami2, K. Dimakou3, I. Panayotou3, E. Roma-Giannikou3, 1Private Dentist, Private, Athens, Greece, 2Dental Shcool University of Athens, Periodology, Athens, Greece, 3St Sofia University Children Hospital, Pediatric Gastroenterology, Athens, Greece

P373. Serology of viral infections in patients with inflammatory bowel disease
Authors:

S. Riestra1, R. de Francisco1, I. Perez1, O. Castano1, L. Blanco1, M. Varela1, L. Rodrigo1, 1Huca, Gastroenterology, Oviedo, Spain

P373. Silent endoscopic relapse in patients with clinical maintained remission and previous deep remission on scheduled treatment with infliximab
P373

Meta-analysis: Does folate supplementation reduce colorectal cancer risk in patients with inflammatory bowel disease?

Authors:

N. Burr*, M. Hull, V. Subramanian

St. James’ University Hospital, Gastroenterology, Leeds, United Kingdom

P374.

Probiotics can extend remission of ulcerative colitis

Authors:

O. Solovyeva, North-Western state medical university named after I.I. Mechnikov, Therapy and clinical pharmacology, Saint-Petersburg, Russian Federation

P374. Fecal transplantation in patients with moderately to severely chronic active ulcerative colitis (UC)
P374. Secondary infliximab treatment failure in Crohn's disease: therapeutic implications of measuring drug and anti-drug antibodies by three different binding assays
Authors:

C. Steenholdt1, J. Brynskov1, O. Thomsen1, L. Munck2, J. Fallingborg3, L. Christensen4, G. Pedersen5, J. Kjeldsen6, K. Bendtzen7, M. Ainsworth1, 1Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark, 2Køge Hospital, Dept of Medical Gastroenterology, Køge, Denmark, 3Aalborg Hospital, Dept of Medical Gastroenterology, Aalborg, Denmark, 4Aarhus Hospital, Dept of Hepatology and Gastroenterology V, Aarhus, Denmark, 5Hvidovre Hospital, Dept of Gastroenterology, Hvidovre, Denmark, 6Odense Hospital, Dept of Medical Gastroenterology S, Odense, Denmark, 7Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Dept. of Infectious Diseases and Rheumatology, Copenhagen, Denmark